NASDAQ$VERV
Verve Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Verve Therapeutics reported its Q4 2021 financial results and pipeline progress.
Verve Therapeutics reported a net loss of $31.3 million for the fourth quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $360.4 million as of December 31, 2021, expected to fund operations into 2024. The company is advancing its VERVE-101 program and planning IND-enabling studies for its ANGPTL3 program.
- Verve is on track to initiate clinical trials for VERVE-101 in the second half of 2022.
- IND-enabling studies for the ANGPTL3 program are anticipated to begin in the second half of 2022.
- Preclinical data in non-human primates demonstrate the potential to re-dose or sequentially dose base editing programs.
- Verve has developed a proprietary GalNAc-LNP delivery system for in vivo liver gene editing treatments.
Headline financials
Revenue & EPS history
Verve Therapeutics · Revenue · Quarterly
$33M
Revenue by segment
Verve Therapeutics · $3.12M total across 1 segment · Q3 2023
- Collaboration Revenue$3.12M—100.0%
Forward guidance
Verve Therapeutics anticipates significant progress in 2022, with the initiation of a clinical trial for VERVE-101 and IND-enabling studies for the ANGPTL3 program.
Tailwinds
- VERVE-101 Clinical Initiation on Track for the Second Half of 2022
- ANGPTL3 Program IND-Enabling Studies Anticipated to Begin in the Second Half of 2022
- Verve plans to expand beyond its PCSK9 and ANGPTL3 programs to develop a suite of single-course gene editing medicines that address root causes of disease.
- Verve’s existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses and capital expenditure requirements into 2024.
- Verve is scheduled to present at multiple upcoming scientific conferences.
Headwinds
- The company has a limited operating history.
- The company's ability to submit applications for its product candidates is subject to timing risks.
- The company's ability to advance its product candidates in clinical trials is subject to risks.
- The company may not be able to correctly estimate the potential patient population and/or market for its product candidates.
- The company may not be able to replicate in clinical trials positive results found in preclinical studies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2021
-1.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-3.8%
Avg return
30 days after
47%
8 / 17 earnings
Positive
+24.4%
Q4 2023
Best reaction
-34.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +3.4% | +5.0% | +48.1% | |
| Q4 2025 | -1.7% | -2.9% | -16.3% | |
| Q3 2024 | +6.0% | +4.5% | +1.0% | |
| Q2 2024 | -12.1% | -20.8% | -1.6% | |
| Q1 2024 | +3.2% | +0.8% | -15.6% | |
| Q4 2023 | +24.4% | +12.7% | -8.2% | |
| Q3 2023 | +11.8% | +4.8% | -13.8% | |
| Q2 2023 | +2.6% | -9.9% | -28.0% | |
| Q1 2023 | -5.2% | -4.5% | -2.6% | |
| Q4 2022 | +7.0% | +3.0% | -20.8% | |
| Q3 2022 | -34.2% | -13.7% | -31.5% | |
| Q2 2022 | +17.5% | +31.2% | +47.0% | |
| Q1 2022 | -4.4% | +12.8% | +15.2% | |
| Q4 2021 | -20.1% | -4.3% | -19.7% | |
| Q3 2021 | -2.7% | -7.8% | -34.7% | |
| Q4 2020 | -1.4% | +5.5% | +7.5% | |
| Q2 2021 | -10.7% | -11.9% | +10.1% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro